Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SEA-CD40 |
Synonyms | |
Therapy Description |
SEA-CD40 is an agonistic monoclonal antibody that targets TNFRSF5 (CD40), potentially resulting in activation of T-cells and enhanced anti-tumor immune response (Cancer Res 2015;75(15 Suppl), Abstract nr 2472). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SEA-CD40 | SEACD40|SEA CD40|Cifurtilimab | CD40 Antibody 14 | SEA-CD40 is an agonistic monoclonal antibody that targets TNFRSF5 (CD40), potentially resulting in activation of T-cells and enhanced anti-tumor immune response (Cancer Res 2015;75(15 Suppl), Abstract nr 2472). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Terminated | USA | 0 |